Phase II neoadjuvant trial of nab-Paclitaxel+Pertuzumab+Trastuzumab followed by Anthracycline based regimen in patients with operable Her2 positive breast cancer

Phase II neoadjuvant trial of nab-Paclitaxel+Pertuzumab+Trastuzumab followed by Anthracycline based regimen in patients with operable Her2 positive breast cancer - OMC-BC05 Study

Status

Active, not recruiting

Phases

Phase 2

Study type

Interventional

Source

JPRN

Registry ID

JPRN-UMIN000038715

Enrollment

Registered

2019-12-01

Start date

2019-12-01

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

breast cancer

Interventions

All patients undergo nab-Paclitaxel + Pertuzumab+Trastuzumab followed by Anthracycline based regimen

Eligibility

Sex/Gender

Female

Inclusion criteria

Inclusion criteria: Her2 positive operable breast cancer

Exclusion criteria

Exclusion criteria: none

Design outcomes

Primary

Measure	Time frame
pathological complete response	—

Secondary

Measure	Time frame
disease free survival objective response rate histological response rate breast conserving rate safety rate of peripheral neuropathy	—

Countries

Japan

Contacts

Public ContactMitsuhiko Mitsuhiko

Osaka Medical College Department of Breast Surgery

sur067@osaka-med.ac.jp+81726831221

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Jul 3, 2026